Welcome to our dedicated page for Bayer Aktien news (Ticker: BAYRY), a resource for investors and traders seeking the latest updates and insights on Bayer Aktien stock.
BAYER AG S/ADR (BAYRY) news covers developments at Bayer AG, a global life science enterprise active in health care and nutrition. Company communications highlight updates across its Pharmaceuticals Division, radiology business and crop science activities, giving investors and observers insight into how Bayer advances its pipeline and product portfolio.
Recent pharmaceutical news emphasizes growth in oncology, cardiology, neurology, immunology and women’s health. Examples include updates on asundexian for secondary stroke prevention, finerenone (Kerendia) in cardiovascular-kidney-metabolic conditions, and oncology assets such as Nubeqa for prostate cancer, Hyrnuo for HER2-mutant non-small cell lung cancer, and Xofigo for metastatic castration-resistant prostate cancer with bone metastases. Bayer also reports on Lynkuet, a hormone-free treatment for moderate to severe hot flashes due to menopause, and a Phase III SUNFLOWER study evaluating Mirena for nonatypical endometrial hyperplasia.
News items also describe Bayer’s work in radiology and molecular imaging, including the low-dose MRI contrast agent gadoquatrane and the acquisition of investigational tracers AT-01 and AT-05 for diagnosing cardiac amyloidosis. Additional coverage highlights cell and gene therapy programs for Parkinson’s disease and ophthalmic conditions, as well as collaborations such as the agreement with Soufflé Therapeutics to develop a heart-targeted siRNA therapy for a form of dilated cardiomyopathy.
On the agriculture side, Bayer Crop Science Canada announcements feature launches like Sivanto Energy for flea beetle control in canola and EverGol Rise for pulse disease control. Together, these updates illustrate how Bayer seeks to execute its mission “Health for all, Hunger for none” through pharmaceutical innovation, diagnostic imaging advances and crop protection solutions.
Bayer (OTC:BAYRY, BAYZF) will feature 11 oral presentations from its cardiovascular, kidney and secondary stroke prevention programs at the ESC Congress 2026 in Munich, August 28–31, 2026. Highlights include late-breaking Phase III data on KERENDIA (finerenone) in chronic kidney disease (CKD) with and without diabetes, hypertensive nephropathy, and heart failure with LVEF ≥40%.
Bayer will also present full Phase III REVEAL results for investigational PET radiotracer I 124 evuzamitide in suspected cardiac amyloidosis, and a new OCEANIC-STROKE analysis on dual antiplatelet therapy and Factor XIa inhibitor asundexian in secondary stroke prevention, alongside multiple additional finerenone analyses.
Bayer (OTC:BAYRY) received a Notice of Compliance from Health Canada expanding the market authorization of LYNKUET (elinzanetant) to treat moderate to severe vasomotor symptoms (VMS) caused by adjuvant endocrine therapy (AET) related to breast cancer. LYNKUET is now the first approved treatment option in Canada for this specific patient group.
This builds on its July 2025 Canadian authorization for VMS associated with menopause. According to Bayer, the expanded indication is supported by the Phase III OASIS-4 trial in women on AET, and by the broader OASIS program where elinzanetant showed significant VMS frequency reductions versus placebo with a placebo-like safety profile.
One A Day (BAYRY, BAYZF), a Bayer brand, introduced a new formula for its Women's Multi Gummy, now providing 1,000 mcg of Biotin per two-gummy serving. According to One A Day, this delivers 2,833% Daily Value of biotin, compared with 150 mcg in several leading women’s multivitamin gummies.
The gummies also include Vitamins A, C, D, E, B3, B5, B6, B12 and Zinc, formulated without artificial sweeteners, high fructose corn syrup or FD&C color additives. The product is positioned to support hair, skin, nails, bone, heart‡, immune and muscle health*, and is available now at Walmart stores nationwide and online.
Bayer (OTC:BAYRY, BAYZF) supported new Economist Enterprise research on integrating self-care into health systems. The report, “Making self-care work: integrating self-care into health systems”, finds that well-governed, evidence-based self-care with reliable information, affordable access and clear referral pathways can improve health outcomes, expand access and ease pressure on overstretched systems.
The research cites existing evidence estimating about US$179 billion in annual economic benefits from self-care and highlights policy priorities: translating commitments into action, ensuring equitable, trusted support, and strengthening measurement and accountability. Country examples include Germany’s “green prescriptions” and Indonesia’s GERMAS movement.
Bayer (OTC:BAYRY) and Henry Ford Health announced a strategic research partnership to expand patient access to clinical trials across Henry Ford’s integrated care network. Henry Ford Health was selected as one of only four U.S. academic health systems in Bayer’s strategic research network.
The collaboration initially targets cardiovascular and renal disease (including thrombosis, heart failure, stroke, and chronic kidney disease), oncology (advanced cancers and targeted therapies), and women’s health (menopausal symptoms and gynecologic conditions). The partners plan to work jointly across the full clinical trial process, using data and technology to design trials and reduce barriers to participation so patients may access investigational therapies closer to home.
Beyond trials, they intend to cooperate on AI, analytics, electronic health record data use, real-world evidence generation, and training in healthcare data science, with the aim of making research faster, more inclusive, and more accessible.
Sabanto, a provider of autonomous retrofit technology for agriculture, announced an oversubscribed Series B financing led by Leaps by Bayer (BAYRY), with participation from Sustainable Forward Capital, InnoVenture Iowa, Fulcrum Global Capital, DCVC, and Yara. The funding is intended to accelerate commercial adoption of Sabanto’s retrofit autonomy platform for row crop farming.
According to Sabanto, proceeds will support expanded commercialization and dealer networks, increased retrofit kit production and deployment, continued software and autonomy development, enhanced customer support and field operations, and faster adoption in the row crop market, while enabling smaller, autonomous equipment to improve efficiency, labor allocation, and potentially soil health.
Bayer (OTC:BAYRY) formed a strategic clinical trial alliance with University of Colorado Anschutz, UCHealth and Children’s Hospital Colorado, its first with an academic medical center. The collaboration targets oncology, cardiovascular, kidney, neurodegenerative disease, cell and gene therapy, women’s health and ophthalmology, aiming to expand trial capacity and patient access to investigational therapies.
Bayer (OTC:BAYRY) announced a collaboration between its One A Day brand and country artist Luke Bryan for limited edition multivitamin gummy bottles.
The One A Day Men & Women’s Multi Gummy bottles, featuring Luke Bryan, are sold exclusively at select Walmart stores nationwide for $9.97 from July through September.
Bayer Group (OTC:BAYRY) is consolidating its U.S. glyphosate business into a distinct entity, Ruveon, based in St. Louis, Missouri. Ruveon will manage U.S. glyphosate pricing, go-to-market strategy, production and logistics while remaining part of Bayer Group.
This move supports the Crop Science division’s Five-Year Framework to enhance growth, resilience and profitability. Dedicated U.S. glyphosate product and commercial teams have joined Ruveon, which will supply Roundup and other glyphosate brands. Alfonso Alba Ordóñez becomes CEO, and Steve Knodle leads commercial business.
Bayer (BAYRY) and Iambic Therapeutics announced a drug discovery collaboration focused on small molecule discovery using Iambic’s AI-driven platform, including Enchant and NeuralPLexer. The partnership targets hard-to-drug targets to enhance Bayer’s early R&D portfolio and pipeline.
Iambic will receive an upfront payment plus potential milestone and royalty payments.